Successful utilization of topical trametinib for neurofibromatosis type I‐associated plexiform neurofibroma

An 11‐year‐old female with neurofibromatosis type 1 (NF‐1) and history of optic glioma presented with a progressive cutaneous plexiform neurofibroma of the breast. The lesion was treated with topical application of a mitogen‐activated protein kinase inhibitor, trametinib, resulting in stable, non‐pr...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric dermatology 2024-11, Vol.41 (6), p.1246-1247
Main Authors: Melnikov, Leonid, Brichta, Lars, Schloemer, Nathan J.
Format: Article
Language:English
Subjects:
administration
Administration, Topical
Child
dermatology
Female
Humans
Inhibitor drugs
Neurofibroma, Plexiform - drug therapy
Neurofibromatosis
Neurofibromatosis 1 - complications
Neurofibromatosis 1 - drug therapy
pediatric
Plexiform neurofibroma
Protein Kinase Inhibitors - therapeutic use
Pyridones - therapeutic use
Pyrimidinones - therapeutic use
Recklinghausen's disease
Skin Neoplasms - drug therapy
therapeutic
topical
Topical application
trametinib
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An 11‐year‐old female with neurofibromatosis type 1 (NF‐1) and history of optic glioma presented with a progressive cutaneous plexiform neurofibroma of the breast. The lesion was treated with topical application of a mitogen‐activated protein kinase inhibitor, trametinib, resulting in stable, non‐progression cutaneous plexiform neurofibroma for greater than 2 years. This case demonstrates the potential application of topical trametinib for NF1‐associated superficial cutaneous plexiform neurofibroma without the toxicities associated with systemic treatment.
ISSN:0736-8046
1525-1470
1525-1470
DOI:10.1111/pde.15710